 |
|
|
| |
Sofosbuvir/Velpatasvir (S/V) for the treatment
of HCV infection among vulnerable inner-city residents:
extending the results of clinical trial
|
| |
| |
EASL 2022 June 22-26 London
Brian Conway1,2, David Truong1, Leo Yamamoto1, Rossitta Yung1, Shawn Sharma1. 1Vancouver Infectious Diseases Centre, Vancouver, Canada; 2Simon Fraser University, Burnaby, Canada
|
| |
|
|
|
|
|
